ABT-751 (Synonyms: E7010)

Name: ABT-751
Brand: MedChemExpress
SKU: HY-13270
Rating: 4.5 (1 reviews)

Cat. No.: HY-13270 Purity: 99.40%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

ABT-751 (E7010) is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer.

For research use only. We do not sell to patients.

ABT-751 Chemical Structure

CAS No. : 141430-65-1

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 75	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 150	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 220	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 350	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of ABT-751:

ABT-751 hydrochloride Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.17 μM Compound: 2, ABT-751	Cytotoxicity against human A2780 cells after 48 to 72 hrs by WAT-1 assay Cytotoxicity against human A2780 cells after 48 to 72 hrs by WAT-1 assay	[PMID: 21126027]
A549	IC₅₀	1.31 μM Compound: ABT-751	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
A549	IC₅₀	1.31 μM Compound: 1, E7010	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24835786]
A549	GI₅₀	1.31 μM Compound: E7010	Antiproliferative activity against human A549 cells assessed as growth inhibition after 24 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as growth inhibition after 24 hrs by SRB assay	[PMID: 25468039]
A549	GI₅₀	1.31 μM Compound: 2; E7010	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	[PMID: 28400235]
A549	IC₅₀	1.376 μM Compound: ABT-751	Antiproliferative activity against human A549 cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human A549 cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]
A549	IC₅₀	1.62 μM Compound: 11; ABT-751	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33479639]
A549	GI₅₀	1.8 μM Compound: 4; E7010	Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 27515320]
A549	GI₅₀	5.33 μM Compound: 4, ABT-751	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26241032]
ACHN	IC₅₀	2.13 μM Compound: 1, E7010	Cytotoxicity against human ACHN cells after 48 hrs by MTT assay Cytotoxicity against human ACHN cells after 48 hrs by MTT assay	[PMID: 24835786]
ASPC1	GI₅₀	4.11 μM Compound: 4, ABT-751	Cytotoxicity against human AsPC1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human AsPC1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26241032]
BT-474	IC₅₀	8.39 μM Compound: ABT-751	Antiproliferative activity against human BT-474 cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human BT-474 cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]
DU-145	GI₅₀	1.2 μM Compound: 4; E7010	Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 27515320]
DU-145	IC₅₀	1.31 μM Compound: ABT-751	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
DU-145	IC₅₀	1.81 μM Compound: 1, E7010	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 24835786]
DU-145	GI₅₀	1.81 μM Compound: E7010	Antiproliferative activity against human DU145 cells assessed as growth inhibition after 24 hrs by SRB assay Antiproliferative activity against human DU145 cells assessed as growth inhibition after 24 hrs by SRB assay	[PMID: 25468039]
DU-145	GI₅₀	1.81 μM Compound: 2; E7010	Growth inhibition of human DU145 cells after 48 hrs by SRB assay Growth inhibition of human DU145 cells after 48 hrs by SRB assay	[PMID: 28400235]
HCCLM3	IC₅₀	0.671 μM Compound: ABT-751	Antiproliferative activity against human HCCLM3 cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human HCCLM3 cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]
HCT-116	IC₅₀	0.9 μM Compound: 2	Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 cell line Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 cell line	[PMID: 12383017]
HCT-116	IC₅₀	0.96 μM Compound: 2	Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 -C1cell line Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 -C1cell line	[PMID: 12383017]
HEK293	IC₅₀	1.31 μM Compound: ABT-751	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HeLa	IC₅₀	0.27 μM Compound: 2, ABT-751	Cytotoxicity against human HeLa cells after 48 to 72 hrs by WAT-1 assay Cytotoxicity against human HeLa cells after 48 to 72 hrs by WAT-1 assay	[PMID: 21126027]
HeLa	IC₅₀	0.355 μM Compound: 5; ABT-751	Growth inhibition of human HeLa cells incubated for 72 hrs by MTT assay Growth inhibition of human HeLa cells incubated for 72 hrs by MTT assay	[PMID: 27172319]
HeLa	IC₅₀	2.18 μM Compound: 11; ABT-751	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33479639]
HeLa	IC₅₀	388 nM Compound: ABT-751	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by XTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by XTT assay	[PMID: 33328100]
HeLa	GI₅₀	4.8 μM Compound: 4; E7010	Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 27515320]
Hep 3B2	GI₅₀	0.84 μM Compound: 4, ABT-751	Cytotoxicity against human Hep3B cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human Hep3B cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26241032]
HepG2	IC₅₀	0.447 μM Compound: 5; ABT-751	Growth inhibition of human HepG2 cells incubated for 72 hrs by MTT assay Growth inhibition of human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 27172319]
HepG2	GI₅₀	2.8 μM Compound: 4; E7010	Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HepG2 cells after 48 hrs by sulforhodamine B assay	[PMID: 27515320]
HL-60	IC₅₀	0.2 μM Compound: 2; E7010	Cytotoxicity against human HL60 cells assessed as inhibition of cell growth after 3 days by MTT assay Cytotoxicity against human HL60 cells assessed as inhibition of cell growth after 3 days by MTT assay	[PMID: 27397495]
HT-29	IC₅₀	0.21 μM Compound: 1; ABT-751	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay	[PMID: 27538123]
HT-29	IC₅₀	0.21 μM Compound: E-7010	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23202849]
HT-29	IC₅₀	1.31 μM Compound: ABT-751	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HT-29	IC₅₀	1.62 μM Compound: 1, E7010	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 24835786]
HT-29	IC₅₀	338.7 nM Compound: 5, ABT751	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay	[PMID: 24106982]
HT-29	IC₅₀	514 nM Compound: ABT-751	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by XTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by XTT assay	[PMID: 33328100]
HUVEC	IC₅₀	9.2 μM Compound: ABT-751	Cytotoxicity against human HUVEC cells assessed as inhibition of cell proliferation measured after 24 hrs by MTS assay Cytotoxicity against human HUVEC cells assessed as inhibition of cell proliferation measured after 24 hrs by MTS assay	[PMID: 33360794]
Jurkat	IC₅₀	0.16 μM Compound: 2, ABT-751	Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis	[PMID: 21126027]
KB	IC₅₀	0.29 μg/mL Compound: E7010	In vitro antiproliferative activity (4 ug/mL) was measured against KB cancer cell line using MTT colorimetric assay In vitro antiproliferative activity (4 ug/mL) was measured against KB cancer cell line using MTT colorimetric assay	[PMID: 10866386]
KB	GI₅₀	0.801 μM Compound: 12; ABT-751, E7010	Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay	[PMID: 32171161]
KB	IC₅₀	250 nM Compound: 1; ABT751	Growth inhibition of human KB cells after 48 hrs by SRB assay Growth inhibition of human KB cells after 48 hrs by SRB assay	[PMID: 30476825]
KB	IC₅₀	251.3 nM Compound: 5, ABT751	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay	[PMID: 24106982]
MC-38	IC₅₀	0.38 μg/mL Compound: E7010	In vitro antiproliferative activity (4 ug/mL) was measured against colon 38 cancer cell line using MTT colorimetric assay In vitro antiproliferative activity (4 ug/mL) was measured against colon 38 cancer cell line using MTT colorimetric assay	[PMID: 10866386]
MCF7	IC₅₀	1.25 μM Compound: 1, E7010	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24835786]
MCF7	GI₅₀	1.25 μM Compound: E7010	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by SRB assay	[PMID: 25468039]
MCF7	GI₅₀	1.53 μM Compound: 2; E7010	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 28400235]
MCF7	IC₅₀	3.79 μM Compound: 5; ABT-751	Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 27172319]
MKN-45	IC₅₀	166 nM Compound: 5, ABT751	Cytotoxicity against human MKN45 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay Cytotoxicity against human MKN45 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay	[PMID: 24106982]
MKN-45	IC₅₀	170 nM Compound: 1; ABT751	Growth inhibition of human MKN45 cells after 48 hrs by SRB assay Growth inhibition of human MKN45 cells after 48 hrs by SRB assay	[PMID: 30476825]
MRC5	GI₅₀	> 100 μM Compound: 2; E7010	Growth inhibition of human MRC5 cells after 48 hrs by SRB assay Growth inhibition of human MRC5 cells after 48 hrs by SRB assay	[PMID: 28400235]
NCI/ADR-RES	IC₅₀	0.29 μM Compound: 2, ABT-751	Cytotoxicity against human NCI-ADR-RES expressing MDR1 cells after 48 to 72 hrs by WAT-1 assay Cytotoxicity against human NCI-ADR-RES expressing MDR1 cells after 48 to 72 hrs by WAT-1 assay	[PMID: 21126027]
NCI-H460	IC₅₀	2.036 μM Compound: ABT-751	Antiproliferative activity against human NCI-H460 cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human NCI-H460 cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]
NCI-H460	IC₅₀	217.7 nM Compound: 5, ABT751	Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay	[PMID: 24106982]
P338	IC₅₀	0.16 μM Compound: 2; E7010	Cytotoxicity against mouse P338 cells assessed as inhibition of cell growth after 3 days by MTT assay Cytotoxicity against mouse P338 cells assessed as inhibition of cell growth after 3 days by MTT assay	[PMID: 27397495]
P388	IC₅₀	0.19 μM Compound: 2	Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388 cell line Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388 cell line	[PMID: 12383017]
P388	IC₅₀	0.32 μg/mL Compound: E7010	In vitro antiproliferative activity (4 ug/mL) was measured against P388 cancer cell line using MTT colorimetric assay In vitro antiproliferative activity (4 ug/mL) was measured against P388 cancer cell line using MTT colorimetric assay	[PMID: 10866386]
P388	IC₅₀	15 μM Compound: 2	Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388/4.0 r-M cell line Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388/4.0 r-M cell line	[PMID: 12383017]
PANC-1	IC₅₀	0.837 μM Compound: ABT-751	Antiproliferative activity against human PANC-1 cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human PANC-1 cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]
PC-3	IC₅₀	0.46 μM Compound: 5; ABT-751	Growth inhibition of human PC3 cells incubated for 72 hrs by MTT assay Growth inhibition of human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 27172319]
PC-3	GI₅₀	0.62 μM Compound: 4, ABT-751	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26241032]
PLC-PRF-5	IC₅₀	0.792 μM Compound: ABT-751	Antiproliferative activity against human PLC-PRF-5 cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human PLC-PRF-5 cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]
RKO	IC₅₀	0.633 μM Compound: ABT-751	Antiproliferative activity against human RKO cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human RKO cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]
SGC-7901	IC₅₀	0.738 μM Compound: ABT-751	Antiproliferative activity against human SGC-7901 cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human SGC-7901 cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]
SK-BR-3	IC₅₀	0.143 μM Compound: ABT-751	Antiproliferative activity against human SK-BR-3 cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human SK-BR-3 cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]
SK-BR-3	IC₅₀	0.74 μM Compound: ABT-751	Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay	[PMID: 22850214]
SW480	IC₅₀	3.421 μM Compound: ABT-751	Antiproliferative activity against human SW480 cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human SW480 cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]
SW-620	IC₅₀	0.19 μM Compound: 2, ABT-751	Cytotoxicity against human SW620 cells after 48 to 72 hrs by WAT-1 assay Cytotoxicity against human SW620 cells after 48 to 72 hrs by WAT-1 assay	[PMID: 21126027]
SW-620	IC₅₀	2.787 μM Compound: ABT-751	Antiproliferative activity against human SW-620 cells assessed as cell viability measured after 72 hrs by MTS method Antiproliferative activity against human SW-620 cells assessed as cell viability measured after 72 hrs by MTS method	[PMID: 33360794]

In Vitro

ABT-751 (2 μM; 4, 8, 24h) can disrupt mitosis, disrupt mitochondrial membrane potential, induce ROS generation and DNA damage in hepatocellular carcinoma-derived Hep-3B cells ^[6].
ABT-751 (2 μM; 4, 8, 24h) can cause DNA damage in Hep-3B cells, inhibit cell proliferation and induce G2/M cell cycle arrest ^[6].
ABT-751 (2 μM; 4, 8, 24h) induces autophagy in TP53-deficient Hep-3B cells by inhibiting the AKT/MTOR signaling pathway, and induces apoptosis through Caspase-dependent, exogenous, and endogenous pathways. Exogenous expression of TP53 gene further increased the autophagy and apoptosis of these cells induced by ABT-751 [6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Line:
Concentration:
Incubation Time:
Result:

In Vivo

ABT-751 (100 mg/kg/day, Oral gavage (p.o.), 5 days on, 5 days off x2, 21 days) has a significant inhibitory effect in neuroblastoma models and can induce significant reduction or regression of tumor volume in rhabdomyosarcoma and nephroblastoma models. ABT-751 has synergistic effect on Vincristine and Paclitaxel (HY-B0015)^[7].
ABT-751 (100 mg/kg/day, Oral gavage (p.o.), 5 days on, 5 days off x2) has a synergistic effect on Docetaxel (HY-B0011) in prostate, NSCLC, and breast tumor xenografts in mice. Improve the inhibitory effect on tumor^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	xenograft models of neuroblastoma, osteosarcoma, Ewing sarcoma rhabdomyosarcoma, medulloblastoma and eight kidney cancer lines (six Wilms tumors, two rhabdoid)^[7]
Dosage:	100 mg/kg
Administration:	Oral gavage (p.o.)
Result:	Had obvious inhibitory effect in neuroblastoma model. Induced significant reduction or regression of tumor volume in rhabdomyosarcoma and nephroblastoma models. Had a synergistic effect on vincristine or Paclitaxel (HY-B0015).

Animal Model:	PC-3 prostate, Calu-6 NSCLC, and breast MDA-MB-468 tumor xenografts in mice^[7]
Dosage:	75, 100 mg/kg
Administration:	Oral gavage (p.o.)
Result:	与 Docetaxel 具有协同作用，提高对肿瘤的抑制作用。

Clinical Trial

Molecular Weight

371.41

Formula

C₁₈H₁₇N₃O₄S

CAS No.

141430-65-1

Appearance

Solid

Color

White to off-white

SMILES

COC1=CC=C(C=C1)S(=O)(NC2=C(N=CC=C2)NC3=CC=C(C=C3)O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (269.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6924 mL	13.4622 mL	26.9244 mL
5 mM	0.5385 mL	2.6924 mL	5.3849 mL
10 mM	0.2692 mL	1.3462 mL	2.6924 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.40%

Select Batch:

Data Sheet (283 KB) SDS (393 KB)

COA (255 KB) LCMS (272 KB)

Handling Instructions (2659 KB)

References

[1]. Huang SM et al.,Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling., Nature. 2009 Oct 1;461(7264):614-20. [Content Brief]

[2]. Elizabeth Fox et al. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors Clin Cancer Res February 15, 2008 14; 1111

[3]. Aggarwal C, et al. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?,Cancer Biol Ther. 2012 Mar;13(5):247-63. [Content Brief]

[4]. Silver M, Rusk A, Phillips B, Beck E, Jankowski M, Philibert J, Hahn K, Hershey E, McKeegan E, Bauch J, Krivoshik A, Khanna C.,Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.,J Vet Intern Med. 2012 Mar-Apr;26(2):349-54. doi: 10.1111/j.1939-1676.2012.00892.x. Epub 2012 Feb 28. [Content Brief]

[5]. Gaynon PS, Harned TM; for the Therapeutic Advances in Childhood LeukemiaLymphoma (TACL) Consortium. [Content Brief]

[6]. Morton CL, et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs. 2007;25(4):285-295. [Content Brief]

[7]. David Frost, et al. ABT-751, an oral antimitotic, shows additive and synergistic activity with docetaxel in preclinical models. Cancer Res 1 May 2007; 67 (9_Supplement): 1426.

[8]. Yoshimatsu K, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997;57(15):3208-3213. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6924 mL	13.4622 mL	26.9244 mL	67.3111 mL
	5 mM	0.5385 mL	2.6924 mL	5.3849 mL	13.4622 mL
	10 mM	0.2692 mL	1.3462 mL	2.6924 mL	6.7311 mL
	15 mM	0.1795 mL	0.8975 mL	1.7950 mL	4.4874 mL
	20 mM	0.1346 mL	0.6731 mL	1.3462 mL	3.3656 mL
	25 mM	0.1077 mL	0.5385 mL	1.0770 mL	2.6924 mL
	30 mM	0.0897 mL	0.4487 mL	0.8975 mL	2.2437 mL
	40 mM	0.0673 mL	0.3366 mL	0.6731 mL	1.6828 mL
	50 mM	0.0538 mL	0.2692 mL	0.5385 mL	1.3462 mL
	60 mM	0.0449 mL	0.2244 mL	0.4487 mL	1.1219 mL
	80 mM	0.0337 mL	0.1683 mL	0.3366 mL	0.8414 mL
	100 mM	0.0269 mL	0.1346 mL	0.2692 mL	0.6731 mL

ABT-751 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

ABT-751 (Synonyms: E7010)

Customer Review

Other Forms of ABT-751:

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

ABT-751 Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

ABT-751 (Synonyms: E7010)

Customer Review

Other Forms of ABT-751:

ABT-751 Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

ABT-751 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

ABT-751 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report